Affiliate-supportedIndependent editorialWe never sell medicationSee how
3-way comparison
Side-by-side breakdown — efficacy, cost, regulatory status, and who each option fits best.
| Attribute | |||
|---|---|---|---|
| Generic name | semaglutide | tirzepatide | tirzepatide |
| Drug class | — | — | — |
| Regulatory status | FDA approved | FDA approved | FDA approved |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Avg retail price | $968/mo | $1135/mo | $1086/mo |
| Without insurance | $968–$1100/mo | $1023–$1330/mo | $349–$1086/mo |
| Savings card max | $25/mo | $25/mo | $25/mo |
| Shortage status |
| resolved |
| resolved |
| resolved |
(semaglutide), (tirzepatide), and (tirzepatide) are GLP-1 medications used for weight management or type 2 diabetes. Key differences: is FDA-approved, is FDA-approved, is FDA-approved.
Effectiveness varies by individual. In clinical trials, tirzepatide-based drugs (Mounjaro, Zepbound) produced ~22% average body-weight loss vs ~15% for semaglutide-based (Ozempic, Wegovy). Discuss with your prescriber.
Cash retail price: $968/mo · $1086/mo · $1135/mo. Compounded versions through telehealth typically run 60-80% less.
Drill down into any pair from the three above for deeper side-by-side analysis.
Dose conversion + transition timeline for each directional switch.
